February 1, 1972British Journal of PharmacologyOpen Access

Clinical investigation of an antagonist at α‐ and β‐adrenoceptors‐AH 5158A

View Full Paper

Ask AI

Bookmark

Why the study?

Does AH 5158A act as an antagonist at alpha- and beta-adrenoceptors in humans?

Population

Human subjects

Design

Other

Authors

JCJoe CollierUniversity of New Brunswick NDN. A. H. DAWNAYSt George's, University of London CNC NachevSt George's Hospital

Discussion

Member takes

Implication

May blunt exercise hemodynamics via dual blockade; leaves open therapeutic positioning in hypertension or HF.

Structured PICO

Does AH 5158A act as an antagonist at alpha- and beta-adrenoceptors in humans?

Population

Human subjects

Intervention

AH 5158A (local infusion in veins/brachial artery, and systemic infusion 0.5-0.9 mg/kg)

Outcome

Alpha- and beta-adrenoceptor blocking action (vascular and systemic responses to noradrenaline, isoprenaline, and exercise)surrogate

AH 5158A demonstrates competitive antagonism at both alpha- and beta-adrenoceptors in humans, effectively attenuating cardiovascular responses to exercise and sympathomimetics.

Cite This Study

Collier et al. (1972) studied this question.

synapsesocial.com/papers/6a9620cf31a50c76aa523d4b https://doi.org/10.1111/j.1476-5381.1972.tb07265.x

View Full Paper

Ask AI

Bookmark

Clinical investigation of an antagonist at α‐ and β‐adrenoceptors‐AH 5158A

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Clinical investigation of an antagonist at α‐ and β‐adrenoceptors‐AH 5158A

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider